Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to investigate the effects of biopsychosocial status, quality of life, functional status and hematological markers on fatigue in individuals with SLE.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Fatigue Assesment Scale | It is a scale consisting 10 items. The maximum score is 50. High score indicates high fatigue. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| FACIT Fatigue Scale | It is scale consisting 13 items. Scores range from 0-52. High score indicates low fatigue | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive Exercise Therapy Approach-Biopsychosocial Questionnaire (BETY-BQ) | It is a scale consist of 30 items. Scores range from 0-120. Higher scores indicate worse biopsychosocial status. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study will include individuals aged 18 and older who are receiving treatment for SLE at a university hospital in Turkey, and meet the inclusion and exclusion criteria.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pamukkale University | Denizli | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D005221 | Fatigue |
| ID | Term |
|---|---|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Short Form 36 (SF-36) Health Survey |
The SF-36 consists of two dimensions, generating a profile of health-related quality of life.These dimensions are: physical health and mental health. Higher scores indicate better health. |
| Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) | The scale consists of 20 questions and includes 8 activities. The total score is obtained by summing the points earned from 8 activities and then dividing that sum by 8. Higher scores indicate worse functional status | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Routine blood test results | Participants' routine blood test results such as neutrophil (NEU (K/uL)) , monocyte (MONO (K/uL)), eosinophil (EO (K/uL)), leukocyte (WBC (K/uL)), lymphocyte (LYM (K/uL)), platelet (PLT (K/uL)) will be recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Routine Blood Test Results | Participants' routine blood test results such as calcium (Ca (mg/dL)), creatinine (mg/dL), c-reactive protein (CRP (mg/L)), uric acid (mg/dL) will be recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Routine Blood Test Results | The participants' rutin blood test such as aspartate aminotransferase (AST IU/L), alanine aminotransferase (ALT IU/L) will be recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Hematological indices | Neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), platelet/lymphocyte (PLR), platelet*neutrophil/lymphocyte (systemic inflammatory index), monocyte/platelet (MTO), neutrophil*monocyte/lymphocyte (systemic inflammatory response index), neutrophil*monocyte*platelet/lymphocyte (systemic inflammation aggregate index) obtained from complete blood counts will be calculated and recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Routine Blood Test Results | Procolcytonin (PCT (%)), erythrocyte distribution width (RDW (%)), platelet distribution width (PDW (%)) levels will be recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Routine Blood Test Results | Erythrocyte distribution width standard deviation (RDW-SD (fL)) will be recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Routine Blood Test Results | C3 complement (g/L) and C4 complement (g/L) levels will be recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Routine Blood Test Results | Blood urea nitrogen (BUN (mg/dL)) levels will be recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |
| Routine Blood Test Results | Sedimentation (mm/h) will be recorded. | Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period. |